Lilly’s PACE Continuous Innovation Indicators Visualize Progress and Value in Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Lilly Oncology has launched a novel value assessment tool that aggregates 40 years of oncology data to measure progress and identify unmet needs in cancer treatments.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Matthew Bin Han Ong
Senior Editor

Login